Optimal Antibody-radionuclide Combinations for Clinical Radioimmunotherapy: a Predictive Model Based on Mouse Pharmacokinetics

Overview

Journal Int J Rad Appl Instrum B

Specialty Nuclear Medicine

Date 1991 Jan 11

PMID 1800459

Citations 7

Authors

E D Yorke

P L Beaumier

B W Wessels

A R Fritzberg

A C Morgan Jr

Affiliations

Soon will be listed here.

Abstract

A theoretical comparison was made of radioimmunotherapy (RIT) dosimetry estimates for eight radionuclides (90Y, 105Rh, 131I, 153Sm, 186Re, 188Re, 198Au, 211At) conjugated to IgG, F(ab')2, and Fab antibody forms. Antibody pharmacokinetics, derived from a nude mouse animal model were combined with appropriate physical data and S values to evaluate absorbed dose to a 0.5 kg centrally located tumor, total body and kidney. Radioimmunoconjugates of F(ab')2 with 90Y, 153Sm and 186Re were predicted to be the most promising for RIT.

Citing Articles

Synthesis and characterization of complexes of the {ReO} core with SNS and S donor ligands.

Femia F, Chen X, Maresca K, Shoup T, Babich J, Zubieta J Inorganica Chim Acta. 2010; 306(1):30-37.

PMID: 20628539 PMC: 2901872. DOI: 10.1016/S0020-1693(00)00144-4.

Exploring oxorhenium '3+1' mixed-ligand complexes carrying the S-benzyl-3-[(2-hydroxyphenyl)methylene]dithiocarbazate [ONS]/monothiol [S] donor set: synthesis and characterization.

Chen X, Femia F, Babich J, Zubieta J Inorganica Chim Acta. 2010; 307(1-2):154-159.

PMID: 20592952 PMC: 2893726. DOI: 10.1016/S0020-1693(00)00193-6.

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Adams G, Schier R, McCALL A, Crawford R, Wolf E, Weiner L Br J Cancer. 1998; 77(9):1405-12.

PMID: 9652755 PMC: 2150193. DOI: 10.1038/bjc.1998.233.

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Casey J, King D, Chaplin L, HAINES A, Pedley R, Mountain A Br J Cancer. 1996; 74(9):1397-405.

PMID: 8912535 PMC: 2074792. DOI: 10.1038/bjc.1996.555.

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

Antoniw P, Farnsworth A, Turner A, HAINES A, Mountain A, Mackintosh J Br J Cancer. 1996; 74(4):513-24.

PMID: 8761364 PMC: 2074671. DOI: 10.1038/bjc.1996.395.